26-Jul-2022 | Zion Market Research
The global autoimmune disease therapeutics market was worth around USD 54.8 billion in 2021 and is estimated to grow to about USD 113.48 billion by 2028, with a compound annual growth rate (CAGR) of approximately 12.9% over the forecast period. The report analyzes the autoimmune disease therapeutics market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the autoimmune disease therapeutics market.
The body's overactive immune system reacts against the chemicals and tissues that are regularly present in the human body to cause autoimmune diseases. The most frequent causes of autoimmune disorders are genetic, infectious, or environmental factors. Autoimmune illness is becoming more common. Autoimmune illnesses affect nearly 50 million Americans, according to the National Institute of Health. Owing to the rising autoimmune disease prevalence and growing public awareness, the global autoimmune disease therapeutics market is estimated to grow substantially during the forecast period.
Growing autoimmune disease prevalence, coupled with increased public awareness, and increased laboratory automation, which enables the simultaneous diagnosis of multiple diagnostic tests to produce quick and error-free results, are some of the factors driving the growth of the global market for autoimmune disease therapeutics. Additionally, technological developments like the creation of novel biomarkers like Humira and Enbrel as well as portable diagnostic point-of-care equipment are anticipated to fuel market growth over the forecast period. However, the major restraints for the worldwide autoimmune disorder therapeutics market are factors such as insufficient funding in developing nations, high costs associated with disease treatment, and non-availability of treatment in developing countries, as well as the emergence of alternative technologies.
The global autoimmune disease therapeutics market is segregated based on drug class, distribution channel, and region. Based on drug class, the market is divided into immunosuppressants, anti-inflammatory drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, and biologics. Among these the anti-inflammatory drugs segment dominates the market, accounting for more than 30 percent of global sales. Based on the distribution channel, the market is classified into hospitals, clinics, drug stores, and independent pharmacies. Over the forecast period, the hospital segment is expected to develop at the fastest rate.
North America dominates the global autoimmune disease therapeutics market and accounted for 42.4% of the global revenue in 2021. This is due to an increase in the prevalence of autoimmune diseases and the existence of government initiatives. The market in this region is expanding as a result of rising healthcare spending, improved healthcare infrastructure, increased use of new technology, and the presence of prominent key players. As per National Institute of Health estimates, the yearly cost of autoimmune disease therapeutics in the U.S. is expected to reach USD 100 billion. Europe is expected to be the second-largest market over the forecast period as a result of increased government attention to enhancing the healthcare infrastructure, rising autoimmune disease incidence, and higher uptake of innovative technologies such as portable diagnostic tools & novel biomarkers. However, in the upcoming years, the market for autoimmune disease therapies will increase in Eastern Europe due to the existence of sizable unexplored prospects.
Key players functioning in the global autoimmune disease therapeutics market include Abbott Laboratories, Chugai Pharmaceutical Co. Ltd., Amgen Inc, Eli Lilly and Company, Genentech Inc, Elan Corporation Plc, F. Hoffmann-La Roche AG, Squibb Company, Merck & Co. Inc, Bayer Schering Pharma AG, Biogen Idec Inc, Johnson & Johnson Inc, and GlaxoSmithKline Plc.
Browse the full “Autoimmune Disease Therapeutics Market by Drug Class (Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, and Biologics), By Distribution Channel (Hospitals, Clinics, Drug Stores, and Independent Pharmacies), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/autoimmune-disease-therapeutics-market
The global autoimmune disease therapeutics market is divided into the following segments:
By Drug Class
By Distribution Channel
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651